Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of troriluzole adjunctive treatment in obsessive-compulsive disorder
CTR20220688Phase 3Completed
- Sponsor
- BioShin
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of troriluzole in obsessive compulsive disorder (OCD), sponsored by BioShin. Primary endpoint: Safety and tolerability based on event frequency per subject. Started Jan 2023; status: completed.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on CTR20220688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220688.